Google
DWTX 株価分析 — Dogwood Therapeutics, Inc. (Healthcare >> Biotechnology)
DWTX に関するよくある質問
DWTXのROE（自己資本利益率）は？
Dogwood Therapeutics, Inc.のROEは-35.13%です。
DWTXの配当利回りは？
Dogwood Therapeutics, Inc.の配当利回りは0.00%です。
DWTXの品質スコア（Quality Score）は？
当社のAIはDWTXの総合財務品質を100点中31点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
DWTXは今が買い時ですか？
当社AIのタイミングスコアは100点中51点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
DWTXはどのセクターに属しますか？
Dogwood Therapeutics, Inc.はHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
DWTX AI Analysis Summary
Our AI summary for DWTX: Dogwood Therapeutics, Inc. (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -35.13%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 51/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 1.64
Price
0.06
(3.80%)
Day Change
|
|
|---|
DWTX, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
47% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 21 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.64 |
| PBV / Sector |
0.66 / 5.20
GREAT
|
| Earning Per Share | -0.87 |
| PE / Sector |
N/A / 19.97
|
| PEG or PE/Growth / Sector |
N/A / 1.22
|
| Average 1M Daily Value |
0.10 M
GREAT
|
| Average 1W Daily Value |
0.05 M
GREAT
|
| Timing Factors |
|
85% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 07:59:45 |
| Symbol | DWTX |
| Name | DOGWOOD THERAPEUTICS, INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 33.63 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 53.13 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 44 Milton Avenue, Alpharetta, GA, United States, 30009
Phone: 866 620 8655
Website: https://dwtx.com
Sector: Healthcare >> Biotechnology
Description: Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is based in Alpharetta, Georgia.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
